Tclin SLC29A1 Equilibrative nucleoside transporter 1

Protein Summary

Description

Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR) and is sodium-independent. It has a higher affinity for adenosine. Inhibited by dipyridamole and dilazep (anticancer chemotherapeutics drugs). This gene is a member of the equilibrative nucleoside transporter family. The gene encodes a transmembrane glycoprotein that localizes to the plasma and mitochondrial membranes and mediates the cellular uptake of nucleosides from the surrounding medium. The protein is categorized as an equilibrative (as opposed to concentrative) transporter that is sensitive to inhibition by nitrobenzylthioinosine (NBMPR). Nucleoside transporters are required for nucleotide synthesis in cells that lack de novo nucleoside synthesis pathways, and are also necessary for the uptake of cytotoxic nucleosides used for cancer and viral chemotherapies. Multiple alternatively spliced variants, encoding the same protein, have been found for this gene. [provided by RefSeq, Jul 2008]

Uniprot Accession IDs

• Q99808
• B3KQV7
• B3KQY5
• Q5T9W9
• Q9UJY2

Gene Name

• SLC29A1

Ensembl ID

• ENST00000371708
• ENSP00000360773
• ENSG00000112759
• ENST00000371713
• ENSP00000360778
• ENST00000371724
• ENSP00000360789
• ENST00000371755
• ENSP00000360820
• ENST00000393844
• ENSP00000377427
• ENST00000427851
• ENSP00000392668

Symbol

• ENT1
• ENT1

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
PubMedID	0.97
kinase perturbation	0.88
gene perturbation	0.87
transcription factor perturbation	0.8
transcription factor binding site profile	0.78

Protein Classes

PANTHER Classes

Protein / Transporter / Equilibrative Nucleoside Transporter 1

DTO Classes

Protein / Transporter / Slc Superfamily Of Solute Carriers / Slc28 And Slc29 Families Of Nucleoside Transporters / Slc29 Family / Equilibrative Nucleoside Transporter 1

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 608.47   (req: < 5)

Gene RIFs: 144   (req: <= 3)

Antibodies: 511   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 608.47   (req: >= 5)

Gene RIFs: 144   (req: > 3)

Antibodies: 511   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 10

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 187

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drugs: 3